<?xml version="1.0" encoding="UTF-8"?>
<p>In the United States, the FDA endorsed an emergency use authorization to permit CQ and HCQ treatment for hospitalized patients for COVID-19 [
 <xref rid="B109-pharmaceuticals-13-00096" ref-type="bibr">109</xref>]. There is a risk of potential toxicity with those medications, including QTc prolongation, cardiomyopathy, and retinal toxicity. Given that, and because of the previously described cases of myocarditis in COVID-19, CQ and HCQ should be cautiously prescribed under close clinical supervision by specialists. Patients with myocarditis are expected to be more susceptible to cardiac adverse effects. In addition, drugâ€“drug interactions should be considered before use, and the patients should be monitored closely for adverse effects during use. The American College of Cardiology has recommended QTc monitoring parameters in that setting [
 <xref rid="B110-pharmaceuticals-13-00096" ref-type="bibr">110</xref>]. 
</p>
